Nucleoside-modified circRNA: Reduced immunogenicity and expansive applications beyond vaccines
circRNA-based cancer vaccines and in vivo chimeric antigen receptor T (CAR-T) cell immunotherapies have been documented successively, but the issue of circRNA immunogenicity remains unresolved.